• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

放线菌中的CRISPR-Cas:仍有许多有待发现之处。

CRISPR-Cas in actinomycetes: still a lot to be discovered.

作者信息

Mitousis Lena, Musiol-Kroll Ewa, Wohlleben Wolfgang

机构信息

Interfaculty Institute for Microbiology and Infection Medicine Tübingen (IMIT), Microbiology/Biotechnology, University of Tübingen, Auf der Morgenstelle 28, 72076 Tübingen, Germany.

Cluster of Excellence, "Controlling Microbes to Fight Infections" (EXC2124), University of Tübingen, 72076 Tübingen, Germany.

出版信息

Microlife. 2025 Jun 12;6:uqaf010. doi: 10.1093/femsml/uqaf010. eCollection 2025.

DOI:10.1093/femsml/uqaf010
PMID:40626243
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12231136/
Abstract

Actinomycetes are important producers of valuable natural products that are applied in medicine or industry. The enzymes necessary for the synthesis of those compounds are encoded in biosynthetic gene clusters (BGCs) in the genome. However, the discovery of new natural products or the improvement of production levels can be hindered by difficulties in genetic manipulation, since standard methods often do not or not efficiently work in actinomycetes. One possible explanation for this could be the presence of nucleic acid defense systems such as CRISPR-Cas. Even though there is a lot of research published about CRISPR-Cas systems in general, the knowledge about the function of CRISPR-Cas in actinomycetes is very limited. Based on sequence data it is known that CRISPR-Cas systems occur in around half of all sequenced actinobacterial genomes. Moreover, analyses of those systems have led to the discovery of new subtypes. The few examples of experimental evidence of CRISPR-Cas activity or , however, point to some special features, regarding crRNA maturation or life-cycle dependent CRISPR-Cas activity. This short review draws attention to this neglected research area and highlights the available data about CRISPR-Cas in actinomycetes.

摘要

放线菌是医学或工业中应用的有价值天然产物的重要生产者。合成这些化合物所需的酶由基因组中的生物合成基因簇(BGCs)编码。然而,由于标准方法在放线菌中往往无法有效发挥作用,基因操作的困难可能会阻碍新天然产物的发现或产量水平的提高。对此的一种可能解释是存在核酸防御系统,如CRISPR-Cas。尽管总体上已经发表了大量关于CRISPR-Cas系统的研究,但关于CRISPR-Cas在放线菌中的功能的知识非常有限。基于序列数据可知,CRISPR-Cas系统存在于约一半已测序的放线菌基因组中。此外,对这些系统的分析导致发现了新的亚型。然而,关于CRISPR-Cas活性的实验证据的少数例子表明,在crRNA成熟或生命周期依赖性CRISPR-Cas活性方面存在一些特殊特征。这篇简短的综述提请人们关注这个被忽视的研究领域,并强调了关于放线菌中CRISPR-Cas的现有数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4c7/12231136/eabad77c0346/uqaf010fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4c7/12231136/eabad77c0346/uqaf010fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4c7/12231136/eabad77c0346/uqaf010fig1.jpg

相似文献

1
CRISPR-Cas in actinomycetes: still a lot to be discovered.放线菌中的CRISPR-Cas:仍有许多有待发现之处。
Microlife. 2025 Jun 12;6:uqaf010. doi: 10.1093/femsml/uqaf010. eCollection 2025.
2
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
3
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
4
Topical antiseptics for chronic suppurative otitis media.用于慢性化脓性中耳炎的局部用抗菌剂。
Cochrane Database Syst Rev. 2025 Jun 9;6(6):CD013055. doi: 10.1002/14651858.CD013055.pub3.
5
Topical versus systemic antibiotics for chronic suppurative otitis media.用于慢性化脓性中耳炎的局部用抗生素与全身用抗生素对比
Cochrane Database Syst Rev. 2025 Jun 9;6(6):CD013053. doi: 10.1002/14651858.CD013053.pub3.
6
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
7
Topical antibiotics with steroids for chronic suppurative otitis media.用于慢性化脓性中耳炎的含类固醇局部用抗生素
Cochrane Database Syst Rev. 2025 Jun 9;6(6):CD013054. doi: 10.1002/14651858.CD013054.pub3.
8
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
9
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂(GLP-1 RAs)减肥效果的网状Meta分析的数量、质量及结果:一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
10
The Lived Experience of Autistic Adults in Employment: A Systematic Search and Synthesis.成年自闭症患者的就业生活经历:系统检索与综述
Autism Adulthood. 2024 Dec 2;6(4):495-509. doi: 10.1089/aut.2022.0114. eCollection 2024 Dec.

本文引用的文献

1
Developing a robust genome editing tool based on an endogenous type I-B CRISPR-Cas system in Saccharopolyspora spinosa.基于内生I-B型CRISPR-Cas系统在多杀菌素链霉菌中开发一种强大的基因组编辑工具。
Sci China Life Sci. 2025 May;68(5):1324-1336. doi: 10.1007/s11427-024-2869-x. Epub 2025 Mar 21.
2
Harnessing the Streptomyces-originating type I-E CRISPR/Cas system for efficient genome editing in Streptomyces.利用源自链霉菌的I-E型CRISPR/Cas系统在链霉菌中进行高效基因组编辑。
Sci China Life Sci. 2025 Apr;68(4):1174-1182. doi: 10.1007/s11427-024-2677-4. Epub 2025 Jan 14.
3
Repurposing endogenous type I-E CRISPR-Cas systems for natural product discovery in Streptomyces.
重新利用内源性 I-E 型 CRISPR-Cas 系统用于链霉菌天然产物的发现。
Nat Commun. 2024 Nov 13;15(1):9833. doi: 10.1038/s41467-024-54196-z.
4
Unleashing the potential: type I CRISPR-Cas systems in actinomycetes for genome editing.释放潜力:放线菌中的 I 型 CRISPR-Cas 系统用于基因组编辑。
Nat Prod Rep. 2024 Sep 18;41(9):1441-1455. doi: 10.1039/d4np00010b.
5
CRISPR-aided genome engineering for secondary metabolite biosynthesis in Streptomyces.CRISPR 辅助的链霉菌次生代谢物生物合成基因组工程。
J Ind Microbiol Biotechnol. 2024 Jan 9;51. doi: 10.1093/jimb/kuae009.
6
Harnessing the endogenous Type I-C CRISPR-Cas system for genome editing in .利用内源性 I-C 型 CRISPR-Cas 系统进行. 的基因组编辑。
Appl Environ Microbiol. 2024 Mar 20;90(3):e0207423. doi: 10.1128/aem.02074-23. Epub 2024 Feb 6.
7
Type-III-A structure of mycobacteria CRISPR-Csm complexes involving atypical crRNAs.分枝杆菌 CRISPR-Csm 复合物的 III-A 型结构,涉及非典型的 crRNA。
Int J Biol Macromol. 2024 Mar;260(Pt 2):129331. doi: 10.1016/j.ijbiomac.2024.129331. Epub 2024 Jan 11.
8
Genomic characterization of the antiviral arsenal of Actinobacteria.放线菌抗病毒武器库的基因组特征。
Microbiology (Reading). 2023 Aug;169(8). doi: 10.1099/mic.0.001374.
9
Cold Cas: reevaluating the occurrence of CRISPR/Cas systems in .冷箱案例:重新评估CRISPR/Cas系统在……中的出现情况
Front Microbiol. 2023 Jun 27;14:1204838. doi: 10.3389/fmicb.2023.1204838. eCollection 2023.
10
Characteristics of subtype III-A CRISPR-Cas system in Mycobacterium tuberculosis: An overview.结核分枝杆菌 III-A 型 CRISPR-Cas 系统的特征:概述。
Infect Genet Evol. 2023 Aug;112:105445. doi: 10.1016/j.meegid.2023.105445. Epub 2023 May 20.